Feed PHGUF
PH

Pharming Group N.V. PHGUF OTC · Healthcare · Netherlands

$1.26 +0.00% +$0.00

Summary

52 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 23% a year over the last 3 years.
  • It holds more cash than debt: $189.1M against $114.2M.

What to watch

  • Operating profit does not even cover the interest on its debt.
  • Earnings per share fell by 40% a year over the last 3 years.
  • The share price is above the Bulios Fair Price.
  • Analysts expect revenue to fall by 3.0% this fiscal year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $1.26

By our assumptions the business is worth less than its shares cost today.

P/E today 37.4 78% lower
5-year average P/E 166.4
P/E today 37.4
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 37.4 USD for 1 USD of yearly profit. Over the last five years it was 166.4 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 23% a year. For the next fiscal year analysts expect revenue to fall by 3.0%. Earnings per share fell by 40% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 USD of revenue goes

Net profit, industry median (Biotechnology) -9.2 USD

Out of every 100 USD of revenue, 6.2 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 4.2 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy